Evidence map›Paper›PMID 32725755›Full record

ArticleCancer medicine2020

Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.

Sandy Srinivas, Ateesha F Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Jui-Hua Tsai, Jarjieh Fang, A Reginald Waldeck, Stacey J Simmons

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment.Health expectations : an international journal of public participation in health care and health policy · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sandy SrinivasStanford University Medical Center, Palo Alto, CA, USA.
Ateesha F MohamedBayer U.S. LLC, Whippany, NJ, USA.
Sreevalsa AppukkuttanBayer U.S. LLC, Whippany, NJ, USA.
Marc BottemanPharmerit International, LP, Bethesda, MD, USA.ORCID 0000-0003-2808-7163
Xinyi NgPharmerit International, LP, Bethesda, MD, USA.ORCID 0000-0002-0736-8276
Namita JoshiPharmerit International, LP, Bethesda, MD, USA.ORCID 0000-0001-5577-2890
Jui-Hua TsaiPharmerit International, LP, Bethesda, MD, USA.
Jarjieh FangPharmerit International, LP, Bethesda, MD, USA.
A Reginald WaldeckBayer U.S. LLC, Whippany, NJ, USA.
Stacey J SimmonsBayer U.S. LLC, Whippany, NJ, USA.
Pharmerit (United States) · USBayer (United States) · USStanford Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently approved second-generation androgen receptor inhibitors (SGARIs) for non-metastatic castration-resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles. We used a discrete choice experiment (DCE) to examine how nmCRPC patients and caregivers perceive the benefits versus risks of these new treatments.

methodsAn online DCE survey with 14 treatment choice questions was administered to nmCRPC patients and caregivers. Each choice question compared two hypothetical medication profiles varying in terms of 5 safety attributes (risk or severity of adverse events [AEs]: fatigue, skin rash, cognitive problems, serious fall, and serious fracture) and two efficacy attributes (duration of overall survival [OS] and time to pain progression). Random parameters logit models were used to estimate each attribute's relative importance. We also estimated the amounts of OS that respondents were willing to forego for a reduction in AEs.

resultsIn total, 143 nmCRPC patients and 149 caregivers viewed the AEs in following order of importance (most to least): serious fracture, serious fall, cognitive problems, fatigue, and skin rash. On average, patients were willing to trade 5.8 and 4.0 months of OS to reduce the risk of serious fracture and fall, respectively, from 3% to 0%; caregivers were willing to trade 6.6 and 5.4 months of OS.

conclusionsnmCRPC patients and caregivers preferred treatments with lower AE burdens and were willing to forego OS to reduce the risk and severity of AEs. Our results highlight the importance of carefully balancing risks and benefits when selecting treatments in this relatively asymptomatic population.

Indexed as

CaregiversChoice BehaviorPatient PreferenceAdultAgedAndrogen AntagonistsAntineoplastic Agents, HormonalCross-Sectional StudiesFemaleHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedPatient SafetyProstatic Neoplasms, Castration-ResistantRisk AssessmentAndrogen AntagonistsAntineoplastic Agents, HormonalCaregiversChoice BehaviorPatientsProstatic Neoplasms, Castration-ResistantRisk Assessment

Identifiers

PMID32725755
PMCPMC7520320
OpenAlexW3045502495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.